Drug Pipeline

Azeliragon Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
4
Top Sponsors
6
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-30 NCT05635734
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma		 Trial completed
2026-05-30 NCT05635734
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma		 Enrollment increased: 18 -> 33 participants
2026-05-30 NCT05635734
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma		 date change Primary completion moved earlier: 2026-12 -> 2026-04-30
2026-05-30 NCT05635734
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma		 date change Completion moved earlier: 2026-12 -> 2026-04-30
2026-05-19 NCT06724926
Concurrent Azeliragon With Craniospinal Irradiation		 overall status: "Recruiting" → "Active Not Recruiting"
2026-05-19 NCT06724926
Concurrent Azeliragon With Craniospinal Irradiation		 Enrollment reduced: 32 -> 21 participants
Active Studies by Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Early Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT05986851 Azeliragon in MGMT Unmethylated Glioblastoma Glioblastoma Active, Not Recruiting
Phase 1/2
NCT05789589 Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain… Cancer Recruiting
Phase 1
NCT06724926 Concurrent Azeliragon With Craniospinal Irradiation Solid Tumor Active, Not Recruiting
Early Phase 1
NCT06831526 Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With… Glioblastoma Recruiting
Sponsors Running Azeliragon Trials
Baptist Health South Florida (1) Cantex Pharmaceuticals (1) NYU Langone Health (1) Washington University School of Medicine (1)
Disease Areas
Glioblastoma (2) Glioma (1)
Get alerts when Azeliragon trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free